---
title: acute promyelocytic leukemia (APL)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[acute myelogenous leukemia (AML)]]

# acute promyelocytic leukemia (APL)

(BloodÂ 2009;113:1875)

Rare,
~8% of AML in U.S.

> 90% cure rates

- Atypical promyelocytes (large, granular cells; [[bilobed nuclei]]) in blood and bone marrow

- Defined by translocation of retinoic acid receptor:Â **t(15;17);Â PML-RARA**Â (>95% of cases)

- **Medical emergency**Â withÂ **DIC**Â andÂ **bleeding**Â common

- Remarkable responses toÂ **[[all-trans-retinoic acid]] (ATRA)**Â &Â **arsenic trioxide (ATO)**Â which induce differentiation of leukemic blasts.
  - âˆ´Â **_early initiation of ATRA if APL suspected_**

## Non-high-risk APL ðŸ

- ATRA + ATO (induction + 4 cycles consolidation)
- â†’ CR ~100%;
- event-free survival 97% and overall survival 99% at 2 yÂ (NEJMÂ 2013;362:111)

## High-risk APL ðŸŽ

- WBC >10k at diagnosis.
- No clear consensus.
- In general, chemo (anthracycline or gemtuzumab ozogamicin) added to ATRA + ATO induction and consolidation.

## [[Differentiation syndrome]] (ATRA)
